Author:
Jiang Tao,Cheng Ruirui,Zhang Guowei,Su Chunxia,Zhao Chao,Li Xuefei,Zhang Jie,Wu Fegnying,Chen Xiaoxia,Gao Guanghui,Li Wei,Cai Weijing,Zhou Fei,Zhao Jing,Xiong Anwen,Ren Shengxiang,Zhang Guojun,Zhou Caicun,Zhang Jun
Funder
National Natural Science Foundation of China
Shanghai Municipal Commission of Health and Family Planning
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference35 articles.
1. Cancer statistics in China, 2015;Chen;CA Cancer J Clin,2016
2. Cancer treatment and survivorship statistics, 2016;Miller;CA Cancer J Clin,2016
3. Metastatic sites and survival in lung cancer;Riihimaki;Lung Cancer,2014
4. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009
5. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011
Cited by
32 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献